126 filings
Page 3 of 7
6-K
zv35 drlybpvu
3 Jan 23
D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care
7:07am
6-K
2vfbe 1a6
12 Dec 22
Meeting Scheduled for January 2023
7:05am
6-K
abvbr9
9 Dec 22
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
m48rw hbf5a9e
9 Nov 22
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
7:05am
6-K
zdh dzxayi4
20 Oct 22
PolyPid Announces Cost Reduction Plan
8:28am
6-K
fs6ggn lvyw3ouig8
28 Sep 22
Report of Foreign Private Issuer
10:34am
6-K
t1xyif8xs
2 Sep 22
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
9:01am
6-K
4i9nl
10 Aug 22
Report of Foreign Private Issuer
4:07pm
6-K
e8j8dgdinvh70je22
10 Aug 22
Report of Foreign Private Issuer
4:05pm
6-K
rmky24vrobjr ow
10 Aug 22
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
6-K
8hj5nb5coe
8 Aug 22
Report of Foreign Private Issuer
4:02pm
6-K
00cwlgyq39re9
3 Aug 22
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX100 in Europe
7:07am
6-K
jje4n zuke0mm
5 Jul 22
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
7:06am
6-K
wxh28fcha
31 May 22
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX100for Prevention of
7:06am
6-K
lcdvlsu9wb
23 May 22
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of
7:05am
6-K
pwhrn7mx
11 May 22
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
7:05am
6-K
41sm2x
3 May 22
Report of Foreign Private Issuer
6:17am
6-K
78pcu221a
6 Apr 22
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
8:36am
6-K
9tk 5jc1ni90
28 Mar 22
Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders
4:00pm
6-K
5q1ot rbcxz26iuykax
2 Mar 22
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical
7:00am